3.1. Adaptive Alterations Induced by Drug Withdrawal and Re-Exposure to Trametinib Are More Pronounced in Trametinib-Resistant Melanoma Cells Displaying Low ERK1/2 Activity Than Those with High ERK1/2 Activity. This evidence concerns the gene MAPK3 and melanoma.